XENE

+ Watchlist + Portfolio

Xenon Pharmaceuticals Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $62.32
52-Week Range: $35.60 – $72.66
Market Cap: $5.78B
P/E (TTM): —
EPS (TTM): -4.74
Dividend Yield: —

Advanced Metrics

Price/Book: 4.65
PEG Ratio: —
Return on Equity: -43.62%
Return on Assets: -28.02%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 21.02
Debt/Equity: 0.01
Total Debt: $6.42M
Free Cash Flow: $-203.55M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.11B

XENE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$9.43M	$0.00	$0.00	$7.50M
Research & Development	$105.77M	$167.51M	$210.39M	$300.94M
Selling, General & Admin	$32.81M	$46.54M	$68.90M	$79.63M
Operating Expenses	$138.58M	$214.05M	$279.30M	$380.57M
Operating Income	-$129.14M	-$214.05M	-$279.30M	-$373.07M
EBITDA	-$127.74M	-$211.99M	-$276.74M	-$370.53M
Pretax Income	-$125.25M	-$182.69M	-$238.42M	-$344.89M
Income Tax	$118.00K	-$292.00K	-$4.09M	$1.02M
Net Income	-$125.37M	-$182.39M	-$234.33M	-$345.91M
Diluted EPS	-2.06	-2.73	-3.01	-4.36
Diluted Shares	60.54M	66.89M	77.89M	79.25M

XENE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$57.24M	$148.64M	$142.71M	$199.16M
Receivables	$986.00K	$874.00K	$1.47M	$1.37M
Current Assets	$600.30M	$644.96M	$635.26M	$560.65M
Total Assets	$754.15M	$964.80M	$798.14M	$633.16M
Current Liabilities	$22.70M	$27.27M	$35.59M	$41.79M
Total Debt	$10.44M	$10.90M	$9.02M	$7.94M
Total Liabilities	$32.65M	$36.88M	$43.24M	$51.40M
Retained Earnings	-$482.75M	-$665.14M	-$899.47M	-$1.25B
Shareholders' Equity	$721.50M	$927.92M	$754.90M	$581.76M
Working Capital	$577.60M	$617.69M	$599.67M	$518.86M

XENE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$101.03M	-$151.11M	-$181.39M	-$279.12M
Capital Expenditure	-$2.89M	-$5.62M	-$3.08M	-$799.00K
Free Cash Flow	-$103.92M	-$156.73M	-$184.46M	-$279.92M
Depreciation & Amortisation	$1.41M	$2.06M	$2.56M	$2.54M
Stock-Based Compensation	$20.38M	$32.37M	$50.72M	$53.71M
Investing Cash Flow	-$293.40M	-$111.39M	$165.00M	$218.00M
Financing Cash Flow	$278.47M	$353.52M	$12.13M	$117.11M
Net Change in Cash	-$115.96M	$91.03M	-$4.26M	$55.99M

XENE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$7.50M	$0.00	$0.00	$0.00	$0.00
Research & Development	$61.20M	$74.98M	$77.05M	$87.70M	$88.51M
Selling, General & Admin	$19.04M	$19.24M	$19.28M	$22.07M	$23.82M
Operating Expenses	$80.24M	$94.23M	$96.34M	$109.77M	$112.33M
Operating Income	-$72.74M	-$94.23M	-$96.34M	-$109.77M	-$112.33M
EBITDA	-$72.08M	-$93.60M	-$95.69M	-$109.16M	-$111.74M
Pretax Income	-$64.62M	-$85.33M	-$90.22M	-$104.72M	-$104.87M
Income Tax	$427.00K	-$626.00K	$677.00K	$538.00K	-$2.57M
Net Income	-$65.05M	-$84.71M	-$90.90M	-$105.26M	-$102.30M
Diluted EPS	-0.83	-1.07	-1.15	-1.31	-1.17
Diluted Shares	78.69M	78.95M	79.25M	80.13M	87.35M

XENE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$116.66M	$135.38M	$104.51M	$199.16M	$545.87M
Receivables	$8.65M	$1.10M	$812.00K	$1.37M	$1.17M
Current Assets	$565.54M	$500.25M	$480.14M	$560.65M	$1.11B
Total Assets	$743.28M	$674.28M	$607.84M	$633.16M	$1.39B
Current Liabilities	$32.03M	$33.05M	$38.34M	$41.79M	$39.81M
Total Debt	$8.68M	$8.71M	$8.33M	$7.94M	$7.49M
Total Liabilities	$39.32M	$40.30M	$48.33M	$51.40M	$48.99M
Retained Earnings	-$964.52M	-$1.05B	-$1.14B	-$1.25B	-$1.35B
Shareholders' Equity	$703.96M	$633.98M	$559.51M	$581.76M	$1.34B
Working Capital	$533.51M	$467.20M	$441.80M	$518.86M	$1.07B

XENE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$61.65M	-$64.23M	-$71.75M	-$81.48M	-$88.90M
Capital Expenditure	-$43.00K	-$157.00K	-$281.00K	-$318.00K	-$133.00K
Free Cash Flow	-$61.70M	-$64.39M	-$72.03M	-$81.80M	-$89.03M
Depreciation & Amortisation	$659.00K	$632.00K	$641.00K	$611.00K	$587.00K
Stock-Based Compensation	$12.17M	$13.71M	$13.71M	$14.12M	$16.89M
Investing Cash Flow	$34.51M	$82.26M	$38.53M	$62.70M	-$407.28M
Financing Cash Flow	$1.15M	$65.00K	$2.36M	$113.54M	$843.01M
Net Change in Cash	-$25.99M	$18.09M	-$30.86M	$94.75M	$346.83M

Market Snapshot

About

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for neurological disorders. The company's programs target epilepsy and other central nervous system conditions, with its lead candidate XEN1101 being developed for focal epilepsy and potentially other neurological indications. Xenon utilizes its expertise in ion channel biology and neuroscience to advance its pipeline.